Urinary Bladder, Overactive
Conditions
Keywords
Overactive bladder, Oxybutynin chloride, OROS
Brief summary
The objective of this study is to evaluate the efficacy of oxybutynin chloride oral osmotic therapeutic system (OROS) on patient-reported outcomes after 12 weeks of treatment by dose escalation in participants with overactive bladder.
Detailed description
This is a multicenter (when more than one hospital or medical school team work on a medical research study), open-label (all people know the identity of the intervention), prospective (study following participants forward in time) Phase 4 study of oxybutynin chloride OROS in participants with overactive bladder. The total study duration will be 12 weeks and will include following visits: Screening (Week -2), Baseline, Week 2, 4, 6 and 12. Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day. Efficacy will primarily be evaluated by assessment of goal achievement (percentage of participants who show a score 4 or 5 in the Likert scale for treatment goal) at Week 12. Participants' safety will also be monitored at each visit.
Interventions
DRUGOxybutynin chloride OROS
Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
Sponsors
Janssen Korea, Ltd., Korea
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants who fulfilled all of the following criteria in their micturition charts completed for 3 days prior to visit 2 (Baseline): mean voiding frequency greater than or equal to 8 times per 24 hours and mean frequency of urinary urgency greater than or equal to 2 times per 24 hours (urgency means sudden and strong urge to urinate and a urinary sensation scale score greater than or equal to 3 in the micturition chart) * Participants with overactive bladder symptoms lasting for 3 months or longer prior to study initiation * Participants who were capable of completing micturition chart and survey questionnaires and provided informed consent to complete them * Participants who could sign on the informed consent form after fully listening to and understanding about characteristics, risks and benefits of the study
Exclusion criteria
* Participants with stress urinary incontinence (not able to control bladder actions) or participants with complicated incontinence dominantly presenting stress urinary incontinence when judging based on medical history * Participants with a hepatic (pertaining to liver) or renal (pertaining to kidneys) disease indicating serum aspartate transaminase (AST \[SGOT\]), alanine transaminase (ALT \[SGPT\]), alkaline phosphatase or creatinnine concentration twice or more of normal upper limit * Participants contraindicated to use anticholinergics including uncontrolled narrow angle glaucoma (increased pressure inside the eye that causes visual problems), urinary retention or gastrointestinal tract retention * Participants experiencing a symptom of acute urinary tract infection (UTI) during the run-in period * Participants with recurrent UTI who had medical history of treatment for UTI symptom 5 times or more in the past one year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Achieved Treatment Goal | Week 12 | Goal achievement was measured by using the 6-point Likert scale (0=not achieved at all and 5=completely achieved). Achievement of treatment goal was defined by a score of 4 or 5 in the Likert scale. Percentage of participants who achieved their treatment goal defined at Baseline (for a maximum of 3 items among the 10 items including incontinence, urinary urgency, frequent urination, nocturnal frequent urination, tenesmus, general health, life habit, activity, pain/pressure pain, and sexual function) was reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline and Week 12 | Participants assessed their bothering for overactive bladder symptom by completing POSQ rated on a 5-point scale: how much they were bothered by daytime frequent urination (frequent urination was required more than the frequency desired during daytime) in the past two weeks. The responses were indicated as: 1 (not bothered at all), 2 (slightly bothered), 3 (average), 4 (strongly bothered) and 5 (very strongly bothered). Number of participants with change from Baseline in the response to this question at Week 12 was reported. |
| Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline and Week 12 | Participants assessed their bothering for overactive bladder symptom by completing POSQ rated on a 5-point scale: how much they were bothered by nighttime frequent urination (waking up from sleep in order to void urine at nighttime \[period from time of going to bed to time planned to wake up in the morning\]) in the past two weeks. The responses were indicated as: 1 (not bothered at all), 2 (slightly bothered), 3 (average), 4 (strongly bothered) and 5 (very strongly bothered). Number of participants with change from Baseline in the response to this question at Week 12 was reported. |
| Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline and Week 12 | Participants assessed their bothering for overactive bladder symptom by completing POSQ rated on a 5-point scale: how much they were bothered by urge urinary incontinence (involuntary voiding or urinary leakage due to sudden micturition desire, not by sneezing, coughing or laughing) in the past two weeks. The responses were indicated as: 1 (not bothered at all), 2 (slightly bothered), 3 (average), 4 (strongly bothered) and 5 (very strongly bothered). Number of participants with change from Baseline in the response to this question at Week 12 was reported. |
| Patient's Perception of Symptom Improvement (PPSI) Score for Overactive Bladder | Week 12 | Participant's perception about decrease in the most bothering symptom of overactive bladder (defined at Baseline) was evaluated by using visual analogue scale (VAS) at Week 12. The total score range was 0 to 100 where 0=symptom disappeared and 100=symptom unchanged or worsened compared to Baseline. |
| Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Week 2, 4, 6 and 12 | The PPTB was used to assess participant's perception about treatment benefit and satisfaction of the study drug. Regarding benefit, participants indicated whether they had any benefit obtained from the treatment. If yes, then the participants indicated whether it was weak benefit or strong benefit. Regarding satisfaction, participants indicated whether they were satisfied with the treatment. If yes, then they indicated if the treatment was slightly satisfactory or very satisfactory. If no, then they indicated if the treatment was slightly unsatisfactory or very unsatisfactory. |
| Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Baseline and Week 12 | Participant's perception about bladder condition was evaluated by using self administered PPBC questionnaire. Participants answered Which of the following statements describes your bladder condition best at the moment? on a 6-point scale: 1= not problematic at all, 2=mild problem, 3=more or less a mild problem, 4=moderate problem, 5=severe problem and 6=very severe problem. |
| Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Score at Week 6 and 12 | Baseline, Week 6, 12 or early discontinuation (ED) | The OAB-q was used to evaluate influence of overactive bladder symptom on health-related quality of life (HRQL). It consisted of 2 parts: Symptom bother (6 items) evaluating how much symptoms related to overactive bladder were bothering in the last 4 weeks and HRQL (13 items) evaluating how general symptoms related to the bladder influenced life in the last 4 weeks. Each item was rated on 6-point Likert scale: 1 (not at all) to 6 (a very great deal). Total score range: 6 to 36 for symptom bother and 13 to 78 for HRQL. Transformed score calculated as (\[Actual total raw score - lowest possible value of raw score\]/range)\*100 for symptom bother where higher score indicates greater symptom bother and as (\[Highest possible raw score-Actual total raw score\]/Raw score range)\*100 for HRQL where higher scores indicate better HRQL. Transformed score range: 0-100 for both, symptom bother and HRQL. |
| Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline and Week 12 | Participants assessed their bothering for overactive bladder symptom by completing POSQ rated on a 5-point scale: how much they were bothered by urinary urgency (strong micturition desire indicated) in the past two weeks. The responses were indicated as: 1 (not bothered at all), 2 (slightly bothered), 3 (average), 4 (strongly bothered) and 5 (very strongly bothered). Number of participants with change from Baseline in the response to this question at Week 12 was reported. |
| Percent Change From Baseline in Mean Voiding Frequency at Week 6 and 12 | Baseline, Week 6, 12 or ED | Mean voiding frequency for 24 hours was calculated as sum of total voiding frequency divided by the number of days when micturition chart was completed. Participants completed micturition chart for 3 days at Baseline, Week 6 and 12/ED. Mean daytime voiding frequency for 24 hours was calculated as sum of total daytime voiding frequency divided by the number of days when micturition chart was completed. Mean nighttime voiding frequency for 24 hours was calculated as sum of total nighttime voiding frequency divided by the number of days when micturition chart was completed. Nighttime voiding was defined as voiding during the sleep cycle. Percent change was calculated as (change value/Baseline value)\*100. |
| Frequency of Urinary Urgency and Urinary Incontinence | Baseline, Week 6, 12 or ED | Urinary urgency means sudden and strong urge to urinate. It was rated by participant on 5-point scale (1=no urinary urgency and 5=urge urinary incontinence). Total frequency of urinary incontinence (UI) for 24 hours was calculated as sum of total frequency of incontinence divided by the number of days when micturition chart was completed. Participants completed micturition chart for 3 days at Baseline, Week 6 and 12/ED. Mean frequency of urinary urgency for 24 hours was calculated as sum of total frequency of urinary urgency divided by the number of days when micturition chart was completed. Urinary urgency was defined as voiding with urinary sensation scale score greater than or equal to 3. |
| Percent Change From Baseline in Frequency of Urinary Urgency and Urinary Incontinence at Week 6 and 12 | Baseline, Week 6, 12 or ED | Urinary urgency means sudden and strong urge to urinate. It was rated by participant on 5-point scale (1=no urinary urgency and 5=urge urinary incontinence). Total frequency of UI for 24 hours was calculated as sum of total frequency of incontinence divided by the number of days when micturition chart was completed. Participants completed micturition chart for 3 days at Baseline, Week 6 and 12/ED. Mean frequency of urinary urgency for 24 hours was calculated as sum of total frequency of urinary urgency divided by the number of days when micturition chart was completed. Urinary urgency was defined as voiding with urinary sensation scale score greater than or equal to 3. Percent change was calculated as (change value/Baseline value)\*100. |
| Mean Severity of Urinary Urgency at Urination | Baseline, Week 6, 12 or ED | Urinary urgency means sudden and strong urge to urinate. It was rated by participant on 5-point scale (1=no urinary urgency, 2=light urinary urgency, 3=moderate urinary urgency, 4=severe urinary urgency and 5=urge urinary incontinence). Mean severity of urinary urgency at urination was calculated as sum of all degrees of urinary urgency measured divided by the voiding frequency. |
| Visual Analogue Scale (VAS) Score for Dry Mouth | Baseline, Week 6, 12 or ED | Severity of dry mouth was evaluated in participants by using VAS: how much dry mouth they have experienced in the past one week. The total score range was 0 (no dry mouth) to 100 (unimaginably most severe dry mouth). |
| Percent Change From Baseline in Visual Analogue Scale (VAS) Score for Dry Mouth at Week 6 and 12 | Baseline, Week 6, 12 or ED | Severity of dry mouth was evaluated in participants by using VAS: how much dry mouth they experienced in the past one week. The total score range was 0 (no dry mouth) to 100 (unimaginably most severe dry mouth). Percent change was calculated as (change value/Baseline value)\*100. |
| Mean Voiding Frequency | Baseline, Week 6, 12 or ED | Mean voiding frequency for 24 hours was calculated as sum of total voiding frequency divided by the number of days when micturition chart was completed. Participants completed micturition chart for 3 days at Baseline, Week 6 and 12/ED. Mean daytime voiding frequency for 24 hours was calculated as sum of total daytime voiding frequency divided by the number of days when micturition chart was completed. Mean nighttime voiding frequency for 24 hours was calculated as sum of total nighttime voiding frequency divided by the number of days when micturition chart was completed. Nighttime voiding was defined as voiding during the sleep cycle. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Oxybutynin Chloride OROS Oxybutynin chloride osmotic release oral system (OROS) tablet at starting dose of 10 milligram (mg) orally once daily. The dose was adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks was continued up to Week 12. Maximum allowed dose was 30 mg per day. | 309 |
| Total | 309 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 38 |
| Overall Study | Lost to Follow-up | 8 |
| Overall Study | Other | 47 |
| Overall Study | Protocol Violation | 2 |
| Overall Study | Withdrawal by Subject | 6 |
Baseline characteristics
| Characteristic | Oxybutynin Chloride OROS |
|---|---|
| Age Continuous | 54.93 Years STANDARD_DEVIATION 12.36 |
| Sex: Female, Male Female | 256 Participants |
| Sex: Female, Male Male | 53 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 289 / 320 |
| serious Total, serious adverse events | 3 / 320 |
Outcome results
Primary
Percentage of Participants Who Achieved Treatment Goal
Goal achievement was measured by using the 6-point Likert scale (0=not achieved at all and 5=completely achieved). Achievement of treatment goal was defined by a score of 4 or 5 in the Likert scale. Percentage of participants who achieved their treatment goal defined at Baseline (for a maximum of 3 items among the 10 items including incontinence, urinary urgency, frequent urination, nocturnal frequent urination, tenesmus, general health, life habit, activity, pain/pressure pain, and sexual function) was reported.
Time frame: Week 12
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Missing data at Week 12 were imputed using last observation carried forward (LOCF).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Oxybutynin Chloride OROS | Percentage of Participants Who Achieved Treatment Goal | 40.45 Percentage of participants |
Secondary
Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Score at Week 6 and 12
The OAB-q was used to evaluate influence of overactive bladder symptom on health-related quality of life (HRQL). It consisted of 2 parts: Symptom bother (6 items) evaluating how much symptoms related to overactive bladder were bothering in the last 4 weeks and HRQL (13 items) evaluating how general symptoms related to the bladder influenced life in the last 4 weeks. Each item was rated on 6-point Likert scale: 1 (not at all) to 6 (a very great deal). Total score range: 6 to 36 for symptom bother and 13 to 78 for HRQL. Transformed score calculated as (\[Actual total raw score - lowest possible value of raw score\]/range)\*100 for symptom bother where higher score indicates greater symptom bother and as (\[Highest possible raw score-Actual total raw score\]/Raw score range)\*100 for HRQL where higher scores indicate better HRQL. Transformed score range: 0-100 for both, symptom bother and HRQL.
Time frame: Baseline, Week 6, 12 or early discontinuation (ED)
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here, 'n' specifies those participants who were evaluable for specific categories at given time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Oxybutynin Chloride OROS | Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Score at Week 6 and 12 | Symptom bother: Baseline (n=309) | 50.08 Units on a scale | Standard Deviation 21.61 |
| Oxybutynin Chloride OROS | Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Score at Week 6 and 12 | Symptom bother: Change at Week 6 (n=251) | -23.73 Units on a scale | Standard Deviation 22.63 |
| Oxybutynin Chloride OROS | Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Score at Week 6 and 12 | Symptom bother: Change at Week 12/ED (n=276) | -25.63 Units on a scale | Standard Deviation 23.68 |
| Oxybutynin Chloride OROS | Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Score at Week 6 and 12 | HRQL: Baseline (n=309) | 53.46 Units on a scale | Standard Deviation 21.2 |
| Oxybutynin Chloride OROS | Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Score at Week 6 and 12 | HRQL: Change at Week 6 (n=251) | 18.96 Units on a scale | Standard Deviation 19.11 |
| Oxybutynin Chloride OROS | Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Score at Week 6 and 12 | HRQL: Change at Week 12/ED (n=276) | 21.32 Units on a scale | Standard Deviation 22.01 |
Secondary
Frequency of Urinary Urgency and Urinary Incontinence
Urinary urgency means sudden and strong urge to urinate. It was rated by participant on 5-point scale (1=no urinary urgency and 5=urge urinary incontinence). Total frequency of urinary incontinence (UI) for 24 hours was calculated as sum of total frequency of incontinence divided by the number of days when micturition chart was completed. Participants completed micturition chart for 3 days at Baseline, Week 6 and 12/ED. Mean frequency of urinary urgency for 24 hours was calculated as sum of total frequency of urinary urgency divided by the number of days when micturition chart was completed. Urinary urgency was defined as voiding with urinary sensation scale score greater than or equal to 3.
Time frame: Baseline, Week 6, 12 or ED
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here, 'n' specifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Oxybutynin Chloride OROS | Frequency of Urinary Urgency and Urinary Incontinence | Urinary urgency: Baseline (n=309) | 9.40 Episodes per day | Standard Deviation 5.28 |
| Oxybutynin Chloride OROS | Frequency of Urinary Urgency and Urinary Incontinence | Urinary urgency: Week 6 (n=244) | 5.11 Episodes per day | Standard Deviation 4.25 |
| Oxybutynin Chloride OROS | Frequency of Urinary Urgency and Urinary Incontinence | Urinary urgency: Week 12/ED (n=245) | 4.31 Episodes per day | Standard Deviation 4.48 |
| Oxybutynin Chloride OROS | Frequency of Urinary Urgency and Urinary Incontinence | UI: Baseline (n=309) | 0.911 Episodes per day | Standard Deviation 3.244 |
| Oxybutynin Chloride OROS | Frequency of Urinary Urgency and Urinary Incontinence | UI: Week 6 (n=244) | 0.213 Episodes per day | Standard Deviation 0.959 |
| Oxybutynin Chloride OROS | Frequency of Urinary Urgency and Urinary Incontinence | UI: Week 12/ED (n=245) | 0.224 Episodes per day | Standard Deviation 1.203 |
Secondary
Mean Severity of Urinary Urgency at Urination
Urinary urgency means sudden and strong urge to urinate. It was rated by participant on 5-point scale (1=no urinary urgency, 2=light urinary urgency, 3=moderate urinary urgency, 4=severe urinary urgency and 5=urge urinary incontinence). Mean severity of urinary urgency at urination was calculated as sum of all degrees of urinary urgency measured divided by the voiding frequency.
Time frame: Baseline, Week 6, 12 or ED
Population: Data was reported in individual participant listings as planned, but not statistically summarized for analysis.
Secondary
Mean Voiding Frequency
Mean voiding frequency for 24 hours was calculated as sum of total voiding frequency divided by the number of days when micturition chart was completed. Participants completed micturition chart for 3 days at Baseline, Week 6 and 12/ED. Mean daytime voiding frequency for 24 hours was calculated as sum of total daytime voiding frequency divided by the number of days when micturition chart was completed. Mean nighttime voiding frequency for 24 hours was calculated as sum of total nighttime voiding frequency divided by the number of days when micturition chart was completed. Nighttime voiding was defined as voiding during the sleep cycle.
Time frame: Baseline, Week 6, 12 or ED
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here, 'n' specifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Oxybutynin Chloride OROS | Mean Voiding Frequency | Daytime: Baseline (n=309) | 10.75 Urinations per day | Standard Deviation 3.71 |
| Oxybutynin Chloride OROS | Mean Voiding Frequency | Daytime: Week 6 (n=244) | 8.22 Urinations per day | Standard Deviation 2.78 |
| Oxybutynin Chloride OROS | Mean Voiding Frequency | Daytime: Week 12/ED (n=245) | 8.08 Urinations per day | Standard Deviation 3.55 |
| Oxybutynin Chloride OROS | Mean Voiding Frequency | Nighttime: Baseline (n=309) | 1.96 Urinations per day | Standard Deviation 1.75 |
| Oxybutynin Chloride OROS | Mean Voiding Frequency | Nighttime: Week 6 (n=244) | 1.34 Urinations per day | Standard Deviation 1.04 |
| Oxybutynin Chloride OROS | Mean Voiding Frequency | Nighttime: Week 12/ED (n=245) | 1.26 Urinations per day | Standard Deviation 1.4 |
| Oxybutynin Chloride OROS | Mean Voiding Frequency | Total: Baseline (n=309) | 12.71 Urinations per day | Standard Deviation 4.56 |
| Oxybutynin Chloride OROS | Mean Voiding Frequency | Total: Week 6 (n=244) | 9.56 Urinations per day | Standard Deviation 3.2 |
| Oxybutynin Chloride OROS | Mean Voiding Frequency | Total: Week 12/ED (n=245) | 9.34 Urinations per day | Standard Deviation 4.22 |
Secondary
Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12
Participants assessed their bothering for overactive bladder symptom by completing POSQ rated on a 5-point scale: how much they were bothered by daytime frequent urination (frequent urination was required more than the frequency desired during daytime) in the past two weeks. The responses were indicated as: 1 (not bothered at all), 2 (slightly bothered), 3 (average), 4 (strongly bothered) and 5 (very strongly bothered). Number of participants with change from Baseline in the response to this question at Week 12 was reported.
Time frame: Baseline and Week 12
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Not bothered, Week 12: Not bothered | 3 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Not bothered, Week 12: Slightly | 3 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Not bothered, Week 12: Average | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Not bothered, Week 12: Strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Not bothered, Week 12: Very strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Slightly, Week 12: Not bothered | 7 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Slightly, Week 12: Slightly | 15 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Slightly, Week 12: Average | 10 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Slightly, Week 12: Strongly | 2 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Slightly, Week 12: Very strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Average, Week 12: Not bothered | 19 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Average, Week 12: Slightly | 22 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Average, Week 12: Average | 21 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Average, Week 12: Strongly | 6 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Average, Week 12: Very strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Strongly, Week 12: Not bothered | 21 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Strongly, Week 12: Slightly | 36 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Strongly, Week 12: Average | 36 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Strongly, Week 12: Strongly | 22 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Strongly, Week 12: Very strongly | 4 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Very strongly, Week 12: Not bothered | 4 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Very strongly, Week 12: Slightly | 17 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Very strongly, Week 12: Average | 12 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Very strongly, Week 12: Strongly | 12 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Daytime Urination at Week 12 | Baseline: Very strongly, Week 12: Very strongly | 3 Participants |
Secondary
Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12
Participants assessed their bothering for overactive bladder symptom by completing POSQ rated on a 5-point scale: how much they were bothered by nighttime frequent urination (waking up from sleep in order to void urine at nighttime \[period from time of going to bed to time planned to wake up in the morning\]) in the past two weeks. The responses were indicated as: 1 (not bothered at all), 2 (slightly bothered), 3 (average), 4 (strongly bothered) and 5 (very strongly bothered). Number of participants with change from Baseline in the response to this question at Week 12 was reported.
Time frame: Baseline and Week 12
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Not bothered, Week 12: Not bothered | 15 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Not bothered, Week 12: Slightly | 3 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Not bothered, Week 12: Average | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Not bothered, Week 12: Strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Not bothered, Week 12: Very strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Slightly, Week 12: Not bothered | 18 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Slightly, Week 12: Slightly | 22 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Slightly, Week 12: Average | 8 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Slightly, Week 12: Strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Slightly, Week 12: Very strongly | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Average, Week 12: Not bothered | 17 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Average, Week 12: Slightly | 24 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Average, Week 12: Average | 22 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Average, Week 12: Strongly | 2 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Average, Week 12: Very strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Strongly, Week 12: Not bothered | 16 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Strongly, Week 12: Slightly | 32 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Strongly, Week 12: Average | 23 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Strongly, Week 12: Strongly | 18 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Strongly, Week 12: Very strongly | 3 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Very strongly, Week 12: Not bothered | 6 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Very strongly, Week 12: Slightly | 23 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Very strongly, Week 12: Average | 7 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Very strongly, Week 12: Strongly | 11 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Frequent Nighttime Urination at Week 12 | Baseline: Very strongly, Week 12: Very strongly | 4 Participants |
Secondary
Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12
Participants assessed their bothering for overactive bladder symptom by completing POSQ rated on a 5-point scale: how much they were bothered by urge urinary incontinence (involuntary voiding or urinary leakage due to sudden micturition desire, not by sneezing, coughing or laughing) in the past two weeks. The responses were indicated as: 1 (not bothered at all), 2 (slightly bothered), 3 (average), 4 (strongly bothered) and 5 (very strongly bothered). Number of participants with change from Baseline in the response to this question at Week 12 was reported.
Time frame: Baseline and Week 12
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Not bothered, Week 12: Not bothered | 63 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Not bothered, Week 12: Slightly | 7 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Not bothered, Week 12: Average | 5 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Not bothered, Week 12: Strongly | 3 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Not bothered, Week 12: Very strongly | 3 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Slightly, Week 12: Not bothered | 28 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Slightly, Week 12: Slightly | 19 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Slightly, Week 12: Average | 2 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Slightly, Week 12: Strongly | 2 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Slightly, Week 12: Very strongly | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Average, Week 12: Not bothered | 19 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Average, Week 12: Slightly | 13 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Average, Week 12: Average | 7 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Average, Week 12: Strongly | 2 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Average, Week 12: Very strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Strongly, Week 12: Not bothered | 14 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Strongly, Week 12: Slightly | 22 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Strongly, Week 12: Average | 13 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Strongly, Week 12: Strongly | 10 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Strongly, Week 12: Very strongly | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Very strongly, Week 12: Not bothered | 15 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Very strongly, Week 12: Slightly | 17 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Very strongly, Week 12: Average | 4 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Very strongly, Week 12: Strongly | 5 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urge Urinary Incontinence at Week 12 | Baseline: Very strongly, Week 12: Very strongly | 1 Participants |
Secondary
Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12
Participants assessed their bothering for overactive bladder symptom by completing POSQ rated on a 5-point scale: how much they were bothered by urinary urgency (strong micturition desire indicated) in the past two weeks. The responses were indicated as: 1 (not bothered at all), 2 (slightly bothered), 3 (average), 4 (strongly bothered) and 5 (very strongly bothered). Number of participants with change from Baseline in the response to this question at Week 12 was reported.
Time frame: Baseline and Week 12
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Not bothered, Week 12: Not bothered | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Not bothered, Week 12: Slightly | 2 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Not bothered, Week 12: Average | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Not bothered, Week 12: Strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Not bothered, Week 12: Very strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Slightly, Week 12: Not bothered | 17 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Slightly, Week 12: Slightly | 29 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Slightly, Week 12: Average | 12 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Slightly, Week 12: Strongly | 6 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Slightly, Week 12: Very strongly | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Average, Week 12: Not bothered | 13 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Average, Week 12: Slightly | 22 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Average, Week 12: Average | 17 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Average, Week 12: Strongly | 2 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Average, Week 12: Very strongly | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Strongly, Week 12: Not bothered | 18 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Strongly, Week 12: Slightly | 41 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Strongly, Week 12: Average | 40 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Strongly, Week 12: Strongly | 16 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Strongly, Week 12: Very strongly | 5 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Very strongly, Week 12: Not bothered | 5 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Very strongly, Week 12: Slightly | 14 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Very strongly, Week 12: Average | 4 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Very strongly, Week 12: Strongly | 4 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Change From Baseline in Response to Primary Overactive Bladder (OAB) Symptom Questionnaire (POSQ): Urinary Urgency at Week 12 | Baseline: Very strongly, Week 12: Very strongly | 6 Participants |
Secondary
Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire
Participant's perception about bladder condition was evaluated by using self administered PPBC questionnaire. Participants answered Which of the following statements describes your bladder condition best at the moment? on a 6-point scale: 1= not problematic at all, 2=mild problem, 3=more or less a mild problem, 4=moderate problem, 5=severe problem and 6=very severe problem.
Time frame: Baseline and Week 12
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here, 'n' specifies those participants who were evaluable for specific categories at given time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Baseline: Not problematic at all (n=309) | 0 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Baseline: Mild problem (n=309) | 4 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Baseline: More or less a mild problem (n=309) | 25 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Baseline: Moderate problem (n=309) | 81 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Baseline: Severe problem (n=309) | 137 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Baseline:Very severe problem (n=309) | 62 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Week 12: Not problematic at all (n=275) | 20 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Week 12: Mild problem (n=275) | 66 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Week 12: More or less a mild problem (n=275) | 85 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Week 12: Moderate problem (n=275) | 63 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Week 12: Severe problem (n=275) | 30 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Bladder Condition (PPBC) Questionnaire | Week 12: Very severe problem (n=275) | 11 Participants |
Secondary
Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire
The PPTB was used to assess participant's perception about treatment benefit and satisfaction of the study drug. Regarding benefit, participants indicated whether they had any benefit obtained from the treatment. If yes, then the participants indicated whether it was weak benefit or strong benefit. Regarding satisfaction, participants indicated whether they were satisfied with the treatment. If yes, then they indicated if the treatment was slightly satisfactory or very satisfactory. If no, then they indicated if the treatment was slightly unsatisfactory or very unsatisfactory.
Time frame: Week 2, 4, 6 and 12
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure and 'n' specifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 2, Weak benefit (n=303) | 184 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 2, Strong benefit (n=303) | 45 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 2, No benefit (n=303) | 73 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 2, Missing (n=303) | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 6, Weak benefit (n=252) | 135 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 4, Weak benefit (n=281) | 155 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 4, Strong benefit (n=281) | 86 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 4, No benefit (n=281) | 39 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 4, Missing (n=281) | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 6, Strong benefit (n=252) | 97 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 6, No benefit (n=252) | 19 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 6, Missing (n=252) | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 12, Weak benefit (n=277) | 117 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 12, Strong benefit (n=277) | 127 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 12, No benefit (n=277) | 32 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Benefit: Week 12, Missing (n=277) | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 2,Slightly satisfactory(n=302) | 168 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 2,Very satisfactory(n=302) | 27 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction:Week 2,Slightly unsatisfactory(n=302) | 52 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 2, Very unsatisfactory (n=302) | 55 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction:Week 4,Slightly unsatisfactory(n=282) | 37 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 4,Slightly satisfactory(n=282) | 160 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 4, Very satisfactory (n=282) | 57 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 4, Very unsatisfactory (n=282) | 26 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 4, Missing (n=282) | 2 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 6,Slightly satisfactory(n=251) | 140 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 6, Very satisfactory (n=251) | 68 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction:Week 6,Slightly unsatisfactory(n=251) | 23 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 6, Very unsatisfactory (n=251) | 19 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 6, Missing (n=251) | 1 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 12,Slightly satisfactory(n=277) | 136 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 12, Very satisfactory (n=277) | 87 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction:Week12,Slightly unsatisfactory(n=277) | 19 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 12, Very unsatisfactory (n=277) | 34 Participants |
| Oxybutynin Chloride OROS | Number of Participants With Response to Patient's Perception of Treatment Benefit (PPTB) Questionnaire | Satisfaction: Week 12, Missing (n=277) | 1 Participants |
Secondary
Patient's Perception of Symptom Improvement (PPSI) Score for Overactive Bladder
Participant's perception about decrease in the most bothering symptom of overactive bladder (defined at Baseline) was evaluated by using visual analogue scale (VAS) at Week 12. The total score range was 0 to 100 where 0=symptom disappeared and 100=symptom unchanged or worsened compared to Baseline.
Time frame: Week 12
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Oxybutynin Chloride OROS | Patient's Perception of Symptom Improvement (PPSI) Score for Overactive Bladder | 38.66 Units on a scale | Standard Deviation 29.73 |
Secondary
Percent Change From Baseline in Frequency of Urinary Urgency and Urinary Incontinence at Week 6 and 12
Urinary urgency means sudden and strong urge to urinate. It was rated by participant on 5-point scale (1=no urinary urgency and 5=urge urinary incontinence). Total frequency of UI for 24 hours was calculated as sum of total frequency of incontinence divided by the number of days when micturition chart was completed. Participants completed micturition chart for 3 days at Baseline, Week 6 and 12/ED. Mean frequency of urinary urgency for 24 hours was calculated as sum of total frequency of urinary urgency divided by the number of days when micturition chart was completed. Urinary urgency was defined as voiding with urinary sensation scale score greater than or equal to 3. Percent change was calculated as (change value/Baseline value)\*100.
Time frame: Baseline, Week 6, 12 or ED
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here, 'n' specifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Oxybutynin Chloride OROS | Percent Change From Baseline in Frequency of Urinary Urgency and Urinary Incontinence at Week 6 and 12 | Urinary urgency: Percent change at Week 6 (n=244) | -39.16 Percent change | Standard Deviation 72.56 |
| Oxybutynin Chloride OROS | Percent Change From Baseline in Frequency of Urinary Urgency and Urinary Incontinence at Week 6 and 12 | Urinary urgency:Percent change at Week12/ED(n=245) | -46.19 Percent change | Standard Deviation 80.39 |
| Oxybutynin Chloride OROS | Percent Change From Baseline in Frequency of Urinary Urgency and Urinary Incontinence at Week 6 and 12 | UI: Percent change at Week 6 (n=75) | -56.42 Percent change | Standard Deviation 107.15 |
| Oxybutynin Chloride OROS | Percent Change From Baseline in Frequency of Urinary Urgency and Urinary Incontinence at Week 6 and 12 | UI: Percent change at Week 12/ED (n=75) | -74.64 Percent change | Standard Deviation 57.92 |
Secondary
Percent Change From Baseline in Mean Voiding Frequency at Week 6 and 12
Mean voiding frequency for 24 hours was calculated as sum of total voiding frequency divided by the number of days when micturition chart was completed. Participants completed micturition chart for 3 days at Baseline, Week 6 and 12/ED. Mean daytime voiding frequency for 24 hours was calculated as sum of total daytime voiding frequency divided by the number of days when micturition chart was completed. Mean nighttime voiding frequency for 24 hours was calculated as sum of total nighttime voiding frequency divided by the number of days when micturition chart was completed. Nighttime voiding was defined as voiding during the sleep cycle. Percent change was calculated as (change value/Baseline value)\*100.
Time frame: Baseline, Week 6, 12 or ED
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here, 'n' specifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Oxybutynin Chloride OROS | Percent Change From Baseline in Mean Voiding Frequency at Week 6 and 12 | Daytime: Percent change at Week 6 (n=244) | -20.36 Percent change | Standard Deviation 22.15 |
| Oxybutynin Chloride OROS | Percent Change From Baseline in Mean Voiding Frequency at Week 6 and 12 | Daytime: Percent change at Week 12/ED (n=245) | -22.47 Percent change | Standard Deviation 25.76 |
| Oxybutynin Chloride OROS | Percent Change From Baseline in Mean Voiding Frequency at Week 6 and 12 | Nighttime: Percent change at Week 6 (n=223) | -13.91 Percent change | Standard Deviation 80.74 |
| Oxybutynin Chloride OROS | Percent Change From Baseline in Mean Voiding Frequency at Week 6 and 12 | Nighttime:Percent change at Week 12/ED (n=224) | -21.54 Percent change | Standard Deviation 80.72 |
| Oxybutynin Chloride OROS | Percent Change From Baseline in Mean Voiding Frequency at Week 6 and 12 | Total: Percent change at Week 6 (n=244) | -22.19 Percent change | Standard Deviation 19.4 |
| Oxybutynin Chloride OROS | Percent Change From Baseline in Mean Voiding Frequency at Week 6 and 12 | Total: Percent change at Week 12/ED (n=245) | -24.90 Percent change | Standard Deviation 22.06 |
Secondary
Percent Change From Baseline in Visual Analogue Scale (VAS) Score for Dry Mouth at Week 6 and 12
Severity of dry mouth was evaluated in participants by using VAS: how much dry mouth they experienced in the past one week. The total score range was 0 (no dry mouth) to 100 (unimaginably most severe dry mouth). Percent change was calculated as (change value/Baseline value)\*100.
Time frame: Baseline, Week 6, 12 or ED
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure and 'n' specifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Oxybutynin Chloride OROS | Percent Change From Baseline in Visual Analogue Scale (VAS) Score for Dry Mouth at Week 6 and 12 | Percent change at Week 6 (n=159) | 210.96 Percent change | Standard Deviation 701.21 |
| Oxybutynin Chloride OROS | Percent Change From Baseline in Visual Analogue Scale (VAS) Score for Dry Mouth at Week 6 and 12 | Percent change at Week 12/ED (n=181) | 171.90 Percent change | Standard Deviation 475.9 |
Secondary
Visual Analogue Scale (VAS) Score for Dry Mouth
Severity of dry mouth was evaluated in participants by using VAS: how much dry mouth they have experienced in the past one week. The total score range was 0 (no dry mouth) to 100 (unimaginably most severe dry mouth).
Time frame: Baseline, Week 6, 12 or ED
Population: ITT population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available. Here 'N' (Number of Participants Analyzed) signifies those participants who were evaluable for this measure and 'n' specifies those participants who were evaluable for specific categories.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Oxybutynin Chloride OROS | Visual Analogue Scale (VAS) Score for Dry Mouth | Baseline (n=308) | 20.30 Units on a scale | Standard Deviation 22.37 |
| Oxybutynin Chloride OROS | Visual Analogue Scale (VAS) Score for Dry Mouth | Week 6 (n=250) | 46.26 Units on a scale | Standard Deviation 26.46 |
| Oxybutynin Chloride OROS | Visual Analogue Scale (VAS) Score for Dry Mouth | Week 12/ED (n=277) | 43.85 Units on a scale | Standard Deviation 29.31 |